CELL KILLING FUSION PEPTIDE EXHIBITING TUMOR CELL-SPECIFIC NECROSIS INDUCTION AND TUMOR REGRESSION
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Nov 20, 2014
app pub date -
Dec 15, 2011
filing date -
Nov 30, 2011
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
A cell-killing peptide, more specifically a cell-killing CKP fusion peptide (CTD7:CKP) is disclosed, wherein a cell-killing peptide (CKP) comprising 10 amino acids in MTD of Noxa protein causing cell death, and 7 amino acids targeting a cancer cell are fused. The cell-killing CKP fusion peptide induces strong cell necrosis at various cancer cell lines (HeLa, HCT116, MCF-7, A549, BJAB, CT26, PC3 and the like) and shows strong tumor regression effect at a mouse tumor model using experimental animals, but does not show apoptosis at normal cells. Therefore, it can be broadly used to human body for treating various diseases requiring cell death, particularly, as an anti-cancer drug.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully